We read with interest the recent article by Mollgard et al. [1][1] concerning the efficacy of single agent lenalidomide (LEN) in patients with chromosome 5 abnormalities and advanced myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). In general, allogeneic stem cell transplantation (
No takes yet. Share an insight, caveat, or question.
Sockel et al. (2012) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: